Literature DB >> 1952578

The role of basophils in asthma.

L M Lichtenstein1, B S Bochner.   

Abstract

The characteristics of the acute and late human response to antigen in the upper and lower airways and in the skin is summarized in TABLE 2. This table makes it clear that while mast cells are responsible for the mediator release of the acute phase, eosinophils and basophils are the cells involved in the mediator release which occurs during the experimental late phase reaction. The pattern of mediators observed during the acute response is quite characteristic of the mast cell. Thus, in the nose, skin, and lungs, the acute response is characterized by significant increases in histamine, PGD2, tryptase, and sometimes LTC4. In the late phase reaction, the pattern of mediator release is characteristic of basophils and eosinophils, and includes histamine, LTC4 (where measurable), and eosinophil-derived proteins, without PGD2 or tryptase. Basophils have been identified at appropriate time-points in each model using morphologic and phenotypic criteria, and their numbers relate to the histamine levels. Finally, treatment with glucocorticosteroids, the most potent drugs available for treating chronic allergic inflammation, obliterates the late phase reaction and decreases both mediator release and the infiltration of eosinophils and basophils. Chronic allergic inflammation is now taken by both the pulmonary and immunologic community as a hallmark of asthma, and it can be stated without equivocation that the basophils are responsible for the mediator release observed in that response.

Entities:  

Mesh:

Year:  1991        PMID: 1952578     DOI: 10.1111/j.1749-6632.1991.tb37960.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation.

Authors:  Mark C Siracusa; Michael R Comeau; David Artis
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Protective and pathological roles of mast cells and basophils.

Authors:  David Voehringer
Journal:  Nat Rev Immunol       Date:  2013-04-05       Impact factor: 53.106

3.  Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children.

Authors:  D A Hill; M C Siracusa; K R Ruymann; E D Tait Wojno; D Artis; J M Spergel
Journal:  Allergy       Date:  2014-02-24       Impact factor: 13.146

Review 4.  Functional heterogeneity in the basophil cell lineage.

Authors:  Mark C Siracusa; Elia D Tait Wojno; David Artis
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

5.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 cause basophil histamine release by a common pathway: downregulation by sodium.

Authors:  A Tedeschi; C Salmaso; M Di Donato; M Lorini; A Miadonna
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

6.  Vascular endothelial growth factor-activated basophils in asthmatics.

Authors:  Krzysztof Gomułka; Jerzy Liebhart; Andrzej Lange; Wojciech Mêdrala
Journal:  Postepy Dermatol Alergol       Date:  2020-06-25       Impact factor: 1.837

7.  Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.

Authors:  Janet M Oliver; Christy A Tarleton; Laura Gilmartin; Tereassa Archibeque; Clifford R Qualls; Lorena Diehl; Bridget S Wilson; Mark Schuyler
Journal:  Int Arch Allergy Immunol       Date:  2009-10-22       Impact factor: 2.749

8.  Basophils as Key Regulators of Allergic Inflammation and Th2-type Immunity.

Authors:  Bernhard F Gibbs
Journal:  World Allergy Organ J       Date:  2008-07       Impact factor: 4.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.